Osteosarcoma Cell-Derived Small Extracellular Vesicles Enhance Osteoclastogenesis and Bone Resorption Through Transferring MicroRNA-19a-3p

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Apr 12

PMID 33842319

Citations 9

Authors

Tingting Luo

XiaoCheng Zhou

Erhui Jiang

Lin Wang

Yaoting Ji

Zhengjun Shang

Affiliations

Soon will be listed here.

Abstract

Osteosarcoma (OS) is the most common primary bone cancer characterized by an aggressive phenotype with bone destruction. The prognosis of OS patients remains unoptimistic with the current treatment strategy. Recently, osteoclasts are believed to play a crucial role in cancer bone metastasis. Thus, osteoclast could be a target both in bone destruction and cancer progression in OS. However, mechanisms governing osteoclastogenesis in OS remain poorly understood. miRNA delivered by small extracellular vesicles (sEVs) could mediate cellular communications. In this study, we investigated the effects of sEVs on osteoclastogenesis and osteoclast function, also clarified the underlying mechanism. We herein found that sEVs promoted pre-osteoclast migration, osteoclastogenesis and resorption by exposing RAW264.7 cells to sEVs derived from OS cells. Bioinformatics analysis showed that phosphatase tension homologue (PTEN), and miR-19a-3p were involved in OS progression. Overexpression of miR-19a-3p or sEVs' miR-19a-3p promoted osteoclast formation and function through PTEN/PI3K/AKT signaling pathway, while inhibition of miR-19a-3p showed the contrary results. The bone marrow macrophages (BMMs) were used to verify the results. OS mice, which were established by subcutaneous injection of OS cells, exhibited increased levels of sEVs' miR-19a-3p in blood. Moreover, micro-computed tomography (CT) and histomorphometry analysis demonstrated that OS mice exhibited osteopenia with increased number of osteoclasts. In conclusion, miR-19a-3p delivery OS cell-derived sEVs promotes osteoclast differentiation and bone destruction through PTEN/phosphatidylinositol 3 -kinase (PI3K)/protein kinase B (AKT) signaling pathway. These findings highlight sEVs packaging of miR-19a-3p as a potential target for prevention and treatment of bone destruction and cancer progression in OS patients. And this finding provides a novel potentially therapeutic target for the bone metastasis.

Citing Articles

Significance of exosomes in osteosarcoma research: a systematic review and meta-analysis of a singular clinical investigation.

Liu X, Ye J, Guo W, Wang J Front Cell Dev Biol. 2024; 12:1473044.

PMID: 39605980 PMC: 11599209. DOI: 10.3389/fcell.2024.1473044.

Osteoclasts in Osteosarcoma: Mechanisms, Interactions, and Therapeutic Prospects.

Gao Y, Pei Y, Zhao F, Wang L Cancer Manag Res. 2023; 15:1323-1337.

PMID: 38027241 PMC: 10661907. DOI: 10.2147/CMAR.S431213.

Decoding the Impact of Tumor Microenvironment in Osteosarcoma Progression and Metastasis.

Nirala B, Yamamichi T, Petrescu D, Shafin T, Yustein J Cancers (Basel). 2023; 15(20).

PMID: 37894474 PMC: 10605493. DOI: 10.3390/cancers15205108.

Biodegradable FePS nanoplatform for efficient treatment of osteosarcoma by combination of gene and NIR-II photothermal therapy.

Luo T, Jiang M, Cheng Z, Lin Y, Chen Y, Zhang Z J Nanobiotechnology. 2023; 21(1):224.

PMID: 37443019 PMC: 10347837. DOI: 10.1186/s12951-023-01961-9.

Functional role of MicroRNA/PI3K/AKT axis in osteosarcoma.

Xiang Y, Yang Y, Liu J, Yang X Front Oncol. 2023; 13:1219211.

PMID: 37404761 PMC: 10315918. DOI: 10.3389/fonc.2023.1219211.

References

Maisano D, Mimmi S, Russo R, Fioravanti A, Fiume G, Vecchio E . Uncovering the Exosomes Diversity: A Window of Opportunity for Tumor Progression Monitoring. Pharmaceuticals (Basel). 2020; 13(8). PMC: 7464894. DOI: 10.3390/ph13080180. View

Sun Z, Liu Q, Hong H, Zhang H, Zhang T . miR-19 promotes osteosarcoma progression by targeting SOCS6. Biochem Biophys Res Commun. 2017; 495(1):1363-1369. DOI: 10.1016/j.bbrc.2017.10.002. View

Yoshida A, Fujiwara T, Uotani K, Morita T, Kiyono M, Yokoo S . Clinical and Functional Significance of Intracellular and Extracellular microRNA-25-3p in Osteosarcoma. Acta Med Okayama. 2018; 72(2):165-174. DOI: 10.18926/AMO/55857. View

Akiyama T, Dass C, Choong P . Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther. 2008; 7(11):3461-9. DOI: 10.1158/1535-7163.MCT-08-0530. View

Cannell I, Kong Y, Bushell M . How do microRNAs regulate gene expression?. Biochem Soc Trans. 2008; 36(Pt 6):1224-31. DOI: 10.1042/BST0361224. View

Chen J, Chen Z . Downregulation of miR-19a inhibits the proliferation and promotes the apoptosis of osteosarcoma cells by regulating the JAK2/STAT3 pathway. Oncol Lett. 2020; 20(5):173. PMC: 7471735. DOI: 10.3892/ol.2020.12033. View

Raimondi L, De Luca A, Gallo A, Costa V, Russelli G, Cuscino N . Osteosarcoma cell-derived exosomes affect tumor microenvironment by specific packaging of microRNAs. Carcinogenesis. 2019; 41(5):666-677. DOI: 10.1093/carcin/bgz130. View

Lou Z, Peng Z, Wang B, Li X, Li X, Zhang X . miR-142-5p promotes the osteoclast differentiation of bone marrow-derived macrophages via PTEN/PI3K/AKT/FoxO1 pathway. J Bone Miner Metab. 2019; 37(5):815-824. DOI: 10.1007/s00774-019-00997-y. View

Kuchimaru T, Hoshino T, Aikawa T, Yasuda H, Kobayashi T, Kadonosono T . Bone resorption facilitates osteoblastic bone metastatic colonization by cooperation of insulin-like growth factor and hypoxia. Cancer Sci. 2014; 105(5):553-9. PMC: 4317828. DOI: 10.1111/cas.12391. View

10.

Meng Q, Dai M, Nie X, Zhang W, Xu X, Li J . MicroRNA-19 contributes to the malignant phenotypes of osteosarcoma in vitro by targeting Pax6. Tumour Biol. 2018; 40(1):1010428317744704. DOI: 10.1177/1010428317744704. View

11.

Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V . Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res. 2007; 67(15):7308-18. DOI: 10.1158/0008-5472.CAN-06-4130. View

12.

Isakoff M, Bielack S, Meltzer P, Gorlick R . Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-35. PMC: 4979196. DOI: 10.1200/JCO.2014.59.4895. View

13.

Podgorski I, Linebaugh B, Koblinski J, Rudy D, Herroon M, Olive M . Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol. 2009; 175(3):1255-69. PMC: 2731144. DOI: 10.2353/ajpath.2009.080906. View

14.

Zhao C, Sun W, Zhang P, Ling S, Li Y, Zhao D . miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway. RNA Biol. 2015; 12(3):343-53. PMC: 4615895. DOI: 10.1080/15476286.2015.1017205. View

15.

Tian K, Di R, Wang L . MicroRNA-23a enhances migration and invasion through PTEN in osteosarcoma. Cancer Gene Ther. 2015; 22(7):351-9. DOI: 10.1038/cgt.2015.27. View

16.

Chen Y, Di Grappa M, Molyneux S, McKee T, Waterhouse P, Penninger J . RANKL blockade prevents and treats aggressive osteosarcomas. Sci Transl Med. 2015; 7(317):317ra197. DOI: 10.1126/scitranslmed.aad0295. View

17.

Bottani M, Banfi G, Lombardi G . Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma. J Clin Med. 2019; 8(10). PMC: 6833074. DOI: 10.3390/jcm8101661. View

18.

Wang M, Xie R, Si H, Shen B . Integrated bioinformatics analysis of miRNA expression in osteosarcoma. Artif Cells Nanomed Biotechnol. 2016; 45(5):936-943. DOI: 10.1080/21691401.2016.1196456. View

19.

Dougall W, Chaisson M . The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev. 2006; 25(4):541-9. DOI: 10.1007/s10555-006-9021-3. View

20.

Gineyts E, Bonnet N, Bertholon C, Millet M, Pagnon-Minot A, Borel O . The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis. Calcif Tissue Int. 2018; 103(5):567-580. DOI: 10.1007/s00223-018-0444-y. View